Canakinumab as first-line biological therapy in Still's disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry.
Vitale A, Caggiano V, Maggio MC, Lopalco G, Emmi G, Sota J, La Torre F, Ruscitti P, Bartoloni E, Conti G, Fabiani C, Mattioli I, Gaggiano C, Cardinale F, Dagna L, Campochiaro C, Giacomelli R, Balistreri A, Laskari K, Tufan A, Ragab G, Almaghlouth IA, Więsik-Szewczyk E, Pereira RM, Frediani B, Iannone F, Sfikakis PP, Cantarini L.
Vitale A, et al. Among authors: lopalco g.
Front Med (Lausanne). 2022 Dec 22;9:1071732. doi: 10.3389/fmed.2022.1071732. eCollection 2022.
Front Med (Lausanne). 2022.
PMID: 36619631
Free PMC article.